X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ELDER PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ELDER PHARMA NOVARTIS/
ELDER PHARMA
 
P/E (TTM) x 385.6 -0.2 - View Chart
P/BV x 33.9 0.1 33,627.9% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 NOVARTIS   ELDER PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
ELDER PHARMA
Jun-14
NOVARTIS/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs758380 199.5%   
Low Rs579188 308.0%   
Sales per share (Unadj.) Rs228.4491.2 46.5%  
Earnings per share (Unadj.) Rs31.7-3.2 -997.5%  
Cash flow per share (Unadj.) Rs32.814.4 227.4%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs297.1376.5 78.9%  
Shares outstanding (eoy) m24.6920.54 120.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.90.6 506.3%   
Avg P/E ratio x21.1-89.3 -23.6%  
P/CF ratio (eoy) x20.419.7 103.5%  
Price / Book Value ratio x2.20.8 298.3%  
Dividend payout %31.50-   
Avg Mkt Cap Rs m16,5055,833 282.9%   
No. of employees `0000.7NA-   
Total wages/salary Rs m1,4452,179 66.3%   
Avg. sales/employee Rs Th8,441.3NM-  
Avg. wages/employee Rs Th2,163.6NM-  
Avg. net profit/employee Rs Th1,173.1NM-  
INCOME DATA
Net Sales Rs m5,63910,089 55.9%  
Other income Rs m1,718257 669.6%   
Total revenues Rs m7,35710,346 71.1%   
Gross profit Rs m-63-792 7.9%  
Depreciation Rs m25361 7.0%   
Interest Rs m552,756 2.0%   
Profit before tax Rs m1,575-3,653 -43.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m792125 632.5%   
Profit after tax Rs m784-65 -1,199.1%  
Gross profit margin %-1.1-7.8 14.1%  
Effective tax rate %50.3-3.4 -1,466.8%   
Net profit margin %13.9-0.6 -2,145.4%  
BALANCE SHEET DATA
Current assets Rs m9,5229,240 103.0%   
Current liabilities Rs m3,2969,998 33.0%   
Net working cap to sales %110.4-7.5 -1,470.1%  
Current ratio x2.90.9 312.6%  
Inventory Days Days3746 79.1%  
Debtors Days Days2860 47.4%  
Net fixed assets Rs m4610,124 0.5%   
Share capital Rs m123206 60.0%   
"Free" reserves Rs m7,2135,582 129.2%   
Net worth Rs m7,3367,734 94.9%   
Long term debt Rs m04,889 0.0%   
Total assets Rs m11,10522,882 48.5%  
Interest coverage x29.5-0.3 -9,064.1%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.50.4 115.2%   
Return on assets %7.611.8 64.2%  
Return on equity %10.7-0.8 -1,264.0%  
Return on capital %22.222.3 99.6%  
Exports to sales %03.0 0.0%   
Imports to sales %00.4 0.0%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs mNA43 0.0%   
Fx inflow Rs m61307 19.8%   
Fx outflow Rs m3,630125 2,897.2%   
Net fx Rs m-3,570181 -1,968.9%   
CASH FLOW
From Operations Rs m1,61011,754 13.7%  
From Investments Rs m687-561 -122.6%  
From Financial Activity Rs m-2,677-6,762 39.6%  
Net Cashflow Rs m-3804,432 -8.6%  

Share Holding

Indian Promoters % 0.0 39.6 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 7.5 26.7%  
FIIs % 1.6 16.8 9.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 36.1 59.6%  
Shareholders   41,647 16,479 252.7%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   BIOCON LTD  WOCKHARDT LTD.  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Dec 14, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - STERLING BIOTECH COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS